<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639599</url>
  </required_header>
  <id_info>
    <org_study_id>haloperidol</org_study_id>
    <nct_id>NCT01639599</nct_id>
  </id_info>
  <brief_title>Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients</brief_title>
  <official_title>Phase 4 Study of Optimal Dose of Haloperidol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low-dose haloperidol is known to be effective for the treatment of postoperative nausea and
      vomiting (PONV). However, precise dose-response studies have not been completed, especially
      in patients at high risk for PONV who require combination therapy. This study sought to
      identify the optimal dose of haloperidol that could be combined with dexamethasone without
      adverse effects in high-risk PONV patients receiving intravenous patient-controlled
      anesthesia (IV PCA) after gynecological laparoscopic surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Female adults with three established PONV risk factors based on Apfel's score were randomised
      into one of three study groups. At the end of anaesthesia, groups H0, H1, and H2 were given
      intravenous (IV) saline, haloperidol 1 mg, and haloperidol 2 mg, respectively. All patients
      were given dexamethasone during the induction of anaesthesia. The overall early (0-2 h) and
      late (2-24 h) incidences of nausea, vomiting, rescue anti-emetic administration, pain, and
      adverse effects (cardiac arrhythmias and extrapyramidal effects) were assessed
      postoperatively. The sedation score was recorded in the postanaesthesia care unit (PACU).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of postoperative nausea and vomiting</measure>
    <time_frame>postoperative 24 hours</time_frame>
    <description>incidence of nausea, vomiting and requirement for rescue antiemetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of extrapyramidal symptoms</measure>
    <time_frame>postoperative 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of cardiac arrhythmia</measure>
    <time_frame>postoperative 2 hours</time_frame>
    <description>cardiac arrhythmia on continuous standard lead EKG monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sedation change in recovery room</measure>
    <time_frame>postoperative 30, 60, 90, and 120 min</time_frame>
    <description>measurement of sedation change using a visual analogue scale (VAS; 0 = wide awake and 10 = maximally asleep)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Gynecological Disease</condition>
  <arm_group>
    <arm_group_label>dexamethasone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dexamethasone 5mg iv during anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexamethasone, haloperiol 1mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 1mg iv 30 min before end of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexamethasone + haloperidol 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 2mg iv 30 min before end of anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone iv injection</intervention_name>
    <description>Dexamethasone 5mg iv during anesthesia induction</description>
    <arm_group_label>dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone, haloperidol</intervention_name>
    <description>dexamethasone + haloperidol 1mg</description>
    <arm_group_label>dexamethasone, haloperiol 1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone, haloperidol</intervention_name>
    <description>Active Comparator: dexamethasone + haloperidol 2mg</description>
    <arm_group_label>dexamethasone + haloperidol 2mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I or II women

          -  Aged 20 65 years, and scheduled for gynecologic laparoscopic surgery and IV
             patient-controlled analgesia (PCA) for postoperative pain control.

        Exclusion Criteria:

          -  Known allergy or intolerance to the study drug

          -  History of cardiac arrhythmia

          -  Psychiatric illness

          -  Chronic treatment with a dopamine antagonist

          -  Use of opioids or steroids within one week of surgery

          -  Use of antiemetic within 24 hours before the study

          -  No ability to use the PCA device

          -  Gastrointestinal, renal, or hepatic disease

          -  Insulin-dependent diabetes or obesity with a body mass index &gt; 35 kg/m2.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Y.E. Moon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>associate proffesor</affiliation>
  </overall_official>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>June 12, 2014</last_update_submitted>
  <last_update_submitted_qc>June 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Young Eun Moon</investigator_full_name>
    <investigator_title>clinical associate professor</investigator_title>
  </responsible_party>
  <keyword>non-smoker</keyword>
  <keyword>female</keyword>
  <keyword>IV PCA</keyword>
  <keyword>patient-controlled analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
    <mesh_term>Genital Diseases, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

